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Regarding “Nutrition impacts the prevalence of
peripheral arterial disease in the United States”
In the article by Lane et al titled “Nutrition impacts the
prevalence of peripheral arterial disease in the United States,”1 the
authors showed that peripheral arterial disease (PAD) could be in
part caused by nutritional behavior. High consumption of vitamin
C, folate, and w-3 fatty acids might prevent this disease, which is
mainly the result of atherosclerosis. Many risk factors also explain
atherosclerosis such as tobacco, dyslipidemia, age, hypertension,
and diabetes. PAD shared the same risk factors with coronary heart
disease (CHD) and some ischemic strokes. It is well known that
nutrition plays a role in CHD development as De Lorgeril and
colleagues demonstrated.2 Good eating habits diminish the risk of
new heart infarct. Nutrition also plays a role in some ischemic
stroke as established by Fung and colleagues.3 So, ischemic vascu-
lar disease (including CHD, PAD, and some ischemic strokes) is in
part due to nutrition. Thus, it will be interesting to evaluate diet in
patients with vascular risk and to give them diet advice in addition
to the best medical or/and the best surgical treatment. This diet
advice might be: Low saturated fatty acids intake, high w-3 poly
unsaturated fatty acids, and high fruit and vegetables intake which
may reduce the risk of vascular disease. A short food-frequency
questionnaire might be very useful to make this evaluation.4
Guillaume Mahe, MD
University Hospital
Angers, France
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Reply
We greatly appreciate the editorial response to our article and
the insightful comments. As the letter has pointed out, previous
authors have suggested that improved nutrition could reduce the
incidence of ischemic heart disease and stroke. The intention of our
study was to explore the associations between nutrient intake and
the prevalence of peripheral vascular disease (PVD).
We wish to highlight the magnitude of the poor nutrition
among Americans with PVD (ankle-brachial index 0.9), num-
bering 16.5 million people. The use of National Health and
Nutrition Examination Survey, with its stratified sampling design,allowed us to make this extrapolation. In addition, we found that
most of these participants reported nutrient intakes far below the
United States Recommended Daily Allowances. This suggests
considerable improvement could be made by instituting preventa-
tive public health measures.
We found that improved consumption of certain nutrients was
associated with a reduced prevalence of PVD, after adjustment for
traditional cardiovascular risk factors. These include antioxidants (vi-
tamins A, C, and E), B vitamins (folate and B6), and polyunsaturated
fatty acids (-3). This would suggest that these nutrients could be
targeted in clinical trials aimed at reducing the risk of PVD.
Many prospective observational studies and randomized clin-
ical trials have previously examined the role of nutrition in PVD.
These studies have been discussed in the article, and their results
have not been consistent. Therefore, we do not wish to overstate
the results of our study. Because this is an observational study, it
cannot be used to determine causality or to make specific dietary
recommendations.
The authors believe that nutritional recommendations should
be made as a result of randomized prospective trials. We think this
recommendation should include a balanced combination of nutri-
ents and healthy foods, such as fruits, vegetables, and lean proteins
containing polyunsaturated fatty acids. This type of heart-healthy
diet could have considerable impact in the reduction of ischemic
heart disease, stroke, and PVD, because they all result from the
process of atherosclerosis.
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Regarding “Suboptimal use of statin therapy in
elderly patients with atherosclerosis: A
population-based study”
In a large population study of elderly patients (mean age 77.1
years) from Canada with symptomatic atherosclerosis, Dr Al-Omran
and colleagues demonstrated an increase in statin therapy over time
among the patients, from 9.8% in 1995 to 55.3% in 2004.1 They
suggest that the use of statins in this elderly population was still
suboptimal and they call for action to further increase statin use in
order to decrease cardiovascular disease. However, evidence suggests
that statin use in the elderly is a double-edged sword2 and might do
more harm than good, or at best trade one disease for another.
The PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) is the only randomized trial that specifically investi-
gated the benefits of statin therapy in an elderly population (mean
age was 75 years at trial entry).2 The trial subjects had prevalent
cardiovascular disease or were at high risk for cardiovascular disease
and were randomized to pravastatin 40 mg daily or placebo for the
3.2 year trial duration. Cancer incidence increased significantly in
subjects randomized to pravastatin, and the increase in cancer
mortality equaled in magnitude to the decrease in coronary heart
disease death in the pravastatin group. All cause mortality was
unchanged, suggesting that statin therapy in this high-risk elderly
population changed the cause, but not the incidence of death.
Statins are immunosuppressive and have been shown to in-
crease the peripheral numbers and functionality of regulatory
T-cells (Tregs) in vivo by increasing the activity of the transcription
factor forkhead box P3.3 Even though this is thought to stabilize
atherosclerotic plaque by reducing effector T-cell responses within
the atheroma,4 it may impair the host antitumor response by
suppressing tumor-specific effector T-cell functions, resulting in
immune tolerance to cancer cells.5 Not unexpectedly, the numbers
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al.5 Moreover, the elderly have depressed immune functions6 and are
more likely than younger subjects to harbormicroscopic foci of cancer
cells. Therefore, further impairment of immune function in the elderly
likely increases the chance of occult tumor growth.
Importantly, statin trials have largely excluded subjects with
prevalent or remote cancer. In practice, elderly patients are treated
with statins regardless of cancer status. It is quite possible that in the
routine treatment of elderly subjects with statins, an increase cancer
incidence and mortality may exceed in magnitude any decrease in
cardiovascular disease morbidity and mortality. Perhaps suboptimal
use of statin therapy in the elderly is actually a blessing in disguise.
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Reply
In response to the letter to the editor by Dr Mark R. Gold-
stein, et al, entitled “Might suboptimal use of statin therapy in the
elderly be a blessing in disguise?,” the authors pointed out that
suboptimal use of statin might do more harm than good in the
elderly because of the increased risk of cancer in these patients.
However, the association between statin use and the development
and/or prevention of cancer has been conflicting.
Although at the experimental level, statins have been demon-
strated to contribute to the development of cancer by acting as
immunoregulators, other studies have shown that statins could trig-
ger cells of certain tumor types to undergo apoptosis,1 which may be
thebasis for the inhibitory effect of statins on cancer cell proliferation.2
In 2002, the PROspective Study of Pravastatin in the Elderly
at Risk (PROSPER) suggested an increased incidence of cancer
diagnosed during the treatment period of 3.2 years (245 [8.5%] in
pravastatin group vs 199 [6.8%] placebo group, P  .02).3 How-ever, these findings have not been replicated consistently in subse-
quent large clinical trials and thus may be attributable to chance
findings. Indeed the Heart Protection Study, the largest clinical trial
to study the benefits of statins in over 20,000 high-risk individuals,
conclusively demonstrated their benefits among a broad population,
including the elderly, without an increased risk for cancer.4
Further, other studies have suggested a large protective effect
of statins on certain cancers in the elderly population. A large
population-based study compared 25,594 non-statin users’ pa-
tients to 37,248 patients using statins showed that statin users had
a statistically significant lower risk for total cancer than nonusers
after adjustment for age (hazard ratio [HR]  0.76, 95% confi-
dence interval [CI]  0.73 to 0.80) and multiple potential con-
founders (HR  0.74, 95% CI  0.70 to 0.78).5
Other studies have suggested a neutral effect of statins on
cancers. A recently published meta-analysis of 20 trials studied
patients treated with statins found that statins have a neutral effect
on cancer and cancer death risks (odds ratio [OR], 1.02; 95% CI,
0.97-1.07) and (OR, 1.01; 95% CI, 0.93-1.09), respectively.6
In conclusion, the currently available evidence consistently
demonstrates significant cardiovascular benefit for statins without
significant harm. An association between statins and cancer has not
been firmly established and cannot be based on the findings of a
single trial. Without conclusive evidence from additional observa-
tional studies and randomized trials that examine the association
between statins and cancer (causation, prevention, or neutral ef-
fect), statin use for the primary and secondary prevention of
cardiovascular adverse events should be continued in the elderly
patients in a similar way as in the younger population.
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